Cardiorenal Safety of OTC Analgesics
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Over-the-counter analgesics are used globally for the relief of acute pain. Although effective, these agents can be associated with adverse effects that may limit their use in some people. In the early 2000s, observations from clinical trials of prescription-strength and supratherapeutic doses of nonselective and cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs (NSAIDs) raised safety concerns regarding the risk of cardiovascular adverse effects with the use of these medications. Subsequently, the US Food and Drug Administration mandated additional study of the cardiovascular safety of NSAIDs for a more comprehensive understanding of their risk. As these data were being collected, and based on a comprehensive review of prescription data and the recommendations of the US Food and Drug Administration Advisory Committee, the warning labels of over-the-counter NSAIDs were updated to emphasize the potential cardiovascular risks of these agents. The recently reported “Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen” (PRECISION) trial, in which participants with osteoarthritis or rheumatoid arthritis and underlying cardiovascular risk factors were treated with prescription-strength celecoxib, ibuprofen, or naproxen, revealed similar rates of cardiovascular events (death from cardiovascular causes including hemorrhagic death, nonfatal myocardial infarction, or nonfatal stroke) among the 3 treatment groups. Although informative, the cardiovascular safety findings derived from PRECISION cannot be extrapolated to the safety of the over-the-counter pain relievers ibuprofen and naproxen, given that the doses used were higher (mean [standard deviation]: ibuprofen, 2045 [246] mg; naproxen, 852 [103] mg) and the durations of use longer (∼20 months) than recommended with over-the-counter use of NSAIDs, which for ibuprofen is up to 10 days. This review discusses the cardiorenal safety of the most commonly used over-the-counter analgesics, ibuprofen, naproxen, and acetaminophen. Available data suggest that there is little cardiovascular risk when over-the-counter formulations of these agents are used as directed in their labels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“No robust evidence supports an association between paracetamol and adverse cardiovascular outcomes (stroke or myocardial infarction) in patients with atherosclerotic heart diseases.94–96”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
Kearney, P. M., Baigent, C., Godwin, J., Halls, H., Emberson, J. R., & Patrono, C. (2006) · BMJ · doi:10.1136/bmj.332.7553.1302 · Cited by 1,445 · cited 10×
“Participants were divided into 4 groups: (1) ASA alone, (2) ASA plus ibuprofen, (3) ASA plus diclofenac, and (4) ASA plus any other NSAIDs.”
BackgroundInfluentialCyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., & FitzGerald, G. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003199 · Cited by 1,394
McGettigan, P., & Henry, D. (2006) · JAMA · doi:10.1001/jama.296.13.jrv60011 · Cited by 1,096
Harirforoosh, S., Asghar, W., & Jamali, F. (2014) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3vw2f · Cited by 960 · cited 1×
“Confounding factors during NSAID use include the fact that inflammatory conditions are associated with CV complications and that some CV medications may have less efficacy or altered pharmacokinetics in inflammatory states.(54,55) Pathophysiologic Effects of NSAIDs on BP Prostaglandin E2 decreases renal Na þ reabsorpt…”
BackgroundHarris, R. C., McKanna, J. A., Akai, Y., Jacobson, H. R., Dubois, R. N., & Breyer, M. D. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117620 · Cited by 860 · cited 1×
“Cyclooxygenase 2 is an inducible enzyme expressed in the brain, kidney, and possibly in the female reproductive system.(37,42,43) Cyclooxygenase 2 expression is increased during states of inflammation.”
BackgroundCardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis
Nissen, S. E., Yeomans, N. D., Solomon, D. H., Lüscher, T. F., Libby, P., Husni, M. E., Graham, D. Y., Borer, J. S., Wisniewski, L. M., Wolski, K. E., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611593 · Cited by 856
Graham, G. G., Davies, M. J., Day, R. O., Mohamudally, A., & Scott, K. F. (2013) · Inflammopharmacology · doi:10.1007/s10787-013-0172-x · Cited by 671
McGettigan, P., & Henry, D. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001098 · Cited by 571 · cited 1×
“24).(36) Most recently, Bally and colleagues(65) performed an individual patient data meta-analysis of studies derived from healthcare databases to examine the time course for the risk of MI, as well as the effects of dose and use duration for commonly used NSAIDs.”
BackgroundBally, M., Dendukuri, N., Rich, B., Nadeau, L., Helin-Salmivaara, A., Garbe, E., & Brophy, J. M. (2017) · BMJ · doi:10.1136/bmj.j1909 · Cited by 528 · cited 2×
“57), respectively.(65) A summary of observational study findings is presented in Table 2.”
BackgroundResultCOX-2 and beyond: approaches to prostaglandin inhibition in human disease
FitzGerald, G. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1225 · Cited by 518 · cited 1×
“Cyclooxygenase 2 expression is increased during states of inflammation.(44) Cyclooxygenase 2 is a key source of PGI2 and is cardioprotective in ischemia–reperfusion injury.”
BackgroundIncreased Prostacyclin Biosynthesis in Patients with Severe Atherosclerosis and Platelet Activation
FitzGerald, G. A., Smith, B., Pedersen, A. K., & Brash, A. R. (1984) · New England Journal of Medicine · doi:10.1056/nejm198404263101701 · Cited by 497
Loll, P. J., Picot, D., & Garavito, R. M. (1995) · Nature Structural Biology · doi:10.1038/nsb0895-637 · Cited by 490
New insights into the use of currently available non-steroidal anti-inflammatory drugs
Brune, & Patrignani, P. (2015) · Journal of Pain Research · doi:10.2147/jpr.s75160 · Cited by 469 · cited 3×
“Adapted from Brune and Patrignani.(37) COX indicates cyclooxygenase; Coxibs, COX-2 inhibitors; GI, gastrointestinal; NSAIDs, nonsteroidal anti-inflammatory drugs; PG, prostaglandin; PGI2, prostacyclin; tNSAIDs, traditional NSAIDs; TxA2, thromboxane.”
BackgroundKargman, S., Charleson, S., Cartwright, M., Frank, J., Riendeau, D., Mancini, J., Evans, J., & O'Neill, G. (1996) · Gastroenterology · doi:10.1053/gast.1996.v111.pm8690211 · Cited by 462
Högestätt, E. D., Jönsson, B. A. G., Ermund, A., Andersson, D. A., Björk, H., Alexander, J. P., Cravatt, B. F., Basbaum, A. I., & Zygmunt, P. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501489200 · Cited by 454 · cited 1×
“Acetaminophen also has endocannabinoid system effects.(49) Mechanistically, the CV risk from nonselective NSAIDs is believed to be caused by profound inhibition of PGI2, which increases platelet reactivity, in conjunction with incomplete 106 Journal of Cardiovascular Pharmacology and Therapeutics 23(2)”
BackgroundEffect of ibuprofen on cardioprotective effect of aspirin
MacDonald, T., & Wei, L. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12509-3 · Cited by 419
Shinmura, K., Tang, X.-L., Wang, Y., Xuan, Y.-T., Liu, S.-Q., Takano, H., Bhatnagar, A., & Bolli, R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.18.10197 · Cited by 381 · cited 1×
“Cyclooxygenase 2 is a key source of PGI2 and is cardioprotective in ischemia–reperfusion injury.(45,46) Hence, selective COX-2 inhibition could lead to decreased antithrombotic PGI2, enhanced leukotriene synthesis, and increased reactive oxygen species and consumption of antithrombotic nitric oxide.”
BackgroundSolomon, S. D., Wittes, J., Finn, P. V., Fowler, R., Viner, J., Bertagnolli, M. M., Arber, N., Levin, B., Meinert, C. L., Martin, B., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.764530 · Cited by 367
Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events
Chan, A. T., Manson, J. E., Albert, C. M., Chae, C. U., Rexrode, K. M., Curhan, G. C., Rimm, E. B., Willett, W. C., & Fuchs, C. S. (2006) · Circulation · doi:10.1161/circulationaha.105.595793 · Cited by 319
García Rodríguez, L. A., Tacconelli, S., & Patrignani, P. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.041 · Cited by 305 · cited 2×
“A population-based retrospective cohort study in participants aged 50 to 84 years between January 2000 and October 2005 with a nested case–control analysis (n 1⁄4 8852 cases; n 1⁄4 20 000 controls) of data from The Health Improvement Network UK database examined the effect of dose on the risk of nonfatal MI associated…”
MethodCyclooxygenase Inhibition and Cardiovascular Risk
Antman, E. M., DeMets, D., & Loscalzo, J. (2005) · Circulation · doi:10.1161/circulationaha.105.568451 · Cited by 282
Kurth, T., Glynn, R. J., Walker, A. M., Chan, K. A., Buring, J. E., Hennekens, C. H., & Gaziano, J. M. (2003) · Circulation · doi:10.1161/01.cir.0000087593.07533.9b · Cited by 254
Brater, D. C. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00369-1 · Cited by 247 · cited 6×
“Although this study showed that coadministration of ibuprofen with low-dose ASA in participants with known CV disease significantly increased the risk of all-cause and CV mortality,69 it is limited by a lack of adjustment for either frequency or actual dose of NSAID.”
BackgroundInfluentialWhite, W. B., Faich, G., Whelton, A., Maurath, C., Ridge, N. J., Verburg, K. M., Geis, G. S., & Lefkowith, J. B. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02265-2 · Cited by 230
Self-citationFosbøl, E., Gislason, G., Jacobsen, S., Folke, F., Hansen, M., Schramm, T., Sørensen, R., Rasmussen, J., Andersen, S., Abildstrom, S., et al. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.204 · Cited by 192
Andersohn, F., Suissa, S., & Garbe, E. (2006) · Circulation · doi:10.1161/circulationaha.105.602425 · Cited by 178
Acetaminophen Increases Blood Pressure in Patients With Coronary Artery Disease
Sudano, I., Flammer, A. J., Périat, D., Enseleit, F., Hermann, M., Wolfrum, M., Hirt, A., Kaiser, P., Hurlimann, D., Neidhart, M., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.956490 · Cited by 175 · cited 2×
“Due to the short-term nature of this study, CV events were not observed.(63) Cardiovascular Events From Clinical Trials There are no single randomized, controlled trials that compared OTC use of ibuprofen, naproxen, or APAP adequate to assess CV risk with low doses of these medications.”
BackgroundFosbøl, E. L., Folke, F., Jacobsen, S., Rasmussen, J. N., Sørensen, R., Schramm, T. K., Andersen, S. S., Rasmussen, S., Poulsen, H. E., Køber, L., et al. (2010) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.109.861104 · Cited by 167 · cited 1×
“There was no evidence of increased risk of coronary death, nonfatal MI, or fatal/nonfatal stroke with naproxen according to dose.(34) McGettigan and Henry(35) compared the risk of serious CV events among participants using COX-2-selective NSAIDs or nonselective NSAIDs in a systematic review and meta-analysis of 23 stu…”
BackgroundLoll, P. J., Picot, D., Ekabo, O., & Garavito, R. M. (1996) · Biochemistry · doi:10.1021/bi952776w · Cited by 164
Clinical Pharmacology and Cardiovascular Safety of Naproxen
Angiolillo, D. J., & Weisman, S. M. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0200-5 · Cited by 158 · cited 1×
“Recommended OTC doses are lower than prescription doses and are designated for much shorter use durations.(27,28) Further, participants in the PRECISION study were at an increased risk of CV events and as such may not represent the typical OTC analgesic consumer.”
BackgroundSelf-citationCOX-2 Inhibitors and Cardiovascular Risk
Cannon, C. P., & Cannon, P. (2012) · Science · doi:10.1126/science.1224398 · Cited by 144 · cited 1×
“Cyclooxygenase Selectivity and Potential CV Ramifications of COX Inhibition Whereas COX-1 inhibition is associated with GI and hematologic side effects, selective inhibition of COX-2 has been associated with CV side effects.(38) Traditional, nonselective NSAIDs decrease the synthesis of prostaglandins via inhibition o…”
BackgroundHirst, J. J. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.2.517 · Cited by 140 · cited 1×
“Cyclooxygenase 2 is an inducible enzyme expressed in the brain, kidney, and possibly in the female reproductive system.(37,42,43) Cyclooxygenase 2 expression is increased during states of inflammation.”
BackgroundMayo, P., Skeith, K. J., Russell, A. S., & Jamali, F. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00314.x · Cited by 133 · cited 1×
“Confounding factors during NSAID use include the fact that inflammatory conditions are associated with CV complications and that some CV medications may have less efficacy or altered pharmacokinetics in inflammatory states.(54,55) Pathophysiologic Effects of NSAIDs on BP Prostaglandin E2 decreases renal Na þ reabsorpt…”
BackgroundCardiovascular Effects of the Cyclooxygenase Inhibitors
White, W. B. (2007) · Hypertension · doi:10.1161/01.hyp.0000258106.74139.25 · Cited by 128
Self-citationGoh, L. Y., Vitry, A. I., Semple, S. J., Esterman, A., & Luszcz, M. A. (2009) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-9-42 · Cited by 126
How and why are non-prescription analgesics used in Scotland?
Porteous, T. (2004) · Family Practice · doi:10.1093/fampra/cmh719 · Cited by 122 · cited 1×
“In a 2005 Scottish postal survey of 2708 individuals 18 years, 37% of respondents reported OTC analgesic use (ibuprofen, APAP, aspirin [ASA], or compound preparations) over the preceding 2 weeks.(18) In Norway, a survey of individuals 20 years conducted between 2006 and 2008 found that 47% of the 39 767 respondents ha…”
BackgroundKoffeman, A. R., Valkhoff, V. E., Çelik, S., Jong, G. W. ‘., Sturkenboom, M., Bindels, P., van der Lei, J., Luijsterburg, P. A. J., & Bierma‐Zeinstra, S. (2014) · British Journal of General Practice · doi:10.3399/bjgp14x677815 · Cited by 105
Guo, Y., Bao, W., Wu, W., Shinmura, K., Tang, X., & Bolli, R. (2000) · Basic Research in Cardiology · doi:10.1007/s003950070024 · Cited by 104 · cited 1×
“Cyclooxygenase 2 is a key source of PGI2 and is cardioprotective in ischemia–reperfusion injury.(45,46) Hence, selective COX-2 inhibition could lead to decreased antithrombotic PGI2, enhanced leukotriene synthesis, and increased reactive oxygen species and consumption of antithrombotic nitric oxide.”
BackgroundDale, O., Borchgrevink, P. C., Fredheim, O. M. S., Mahic, M., Romundstad, P., & Skurtveit, S. (2015) · BMC Public Health · doi:10.1186/s12889-015-1774-6 · Cited by 86 · cited 1×
“In Norway, a survey of individuals 20 years conducted between 2006 and 2008 found that 47% of the 39 767 respondents had used OTC analgesics (APAP, NSAIDs, ASA) at least once per week over the last month.(16) Beginning in 2000,(21) an increased cardiovascular (CV) event risk was noted within some patient populations d…”
BackgroundIbuprofen and Paracetamol: Relative Safety in Non-prescription Dosages
Rainsford, K. D., Roberts, S. C., & Brown, S. A. (1997) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1997.tb06809.x · Cited by 82 · cited 2×
“Recommended OTC doses are lower than prescription doses and are designated for much shorter use durations.(27,28) Further, participants in the PRECISION study were at an increased risk of CV events and as such may not represent the typical OTC analgesic consumer.”
BackgroundHouston, M. C. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430100075009 · Cited by 79 · cited 1×
“Similar percentages of participants in all groups had 10 mm Hg increases in either SBP (17%, 16%, and 15%, respectively) or DBP (2%, 9%, and 9%, respectively).(60) The risk of CV events is increased with long-term use of NSAIDs and COX-2 inhibitors in patients with coronary artery disease(61,62); thus, APAP is commonl…”
BackgroundThe Safety Profile of Nonprescription Ibuprofen in Multiple‐Dose Use: A Meta‐Analysis
Kellstein, D. E., Waksman, J. A., Furey, S. A., Binstok, G., & Cooper, S. A. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/009127009903900513 · Cited by 60 · cited 1×
“7%]).(58) Patients With Hypertension Furey and coworkers(59) investigated the renal effects of ibuprofen 400 mg 3 times a day compared with APAP 650 mg 3 times a day and ASA 650 mg 3 times a day for 7 days in a randomized, double-blind study of 25 patients aged 60 years with hydrochlorothiazide-treated stage 1 hyperte…”
BackgroundSafety profile of over-the-counter naproxen sodium
DeArmond, B., Francisco, C. A., Lin, J., Huang, F.-Y., Halladay, S. C., Bartizek, R. D., & Skare, K. L. (1995) · Clinical Therapeutics · doi:10.1016/0149-2918(95)80036-0 · Cited by 60 · cited 1×
“Rates of AEs were low and similar among all active treatment groups.(57) Rainsford and colleagues(27) evaluated the safety of OTC ibuprofen and APAP from 96 randomized, double-blind studies.”
van der Linden, M. W., van der Bij, S., Welsing, P. M. J., Kuipers, E. J., & Herings, R. M. C. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.087254 · Cited by 60 · cited 2×
“A nested case–control study from the Netherlands examined the risk of first hospitalization for MI or other CV events (unstable angina, cerebrovascular accident, transient ischemic attack [TIA]) in COX-2 and traditional NSAID users in the PHARMO Record Linkage System between January 1, 2001, and December 31, 2004.(32)…”
BackgroundMethodNon-steroidal anti-inflammatory drugs and the continuum of renal dysfunction.
Epstein, M. (2002) · PubMed · Cited by 55
Frequency of use of acetaminophen, nonsteroidal anti‐inflammatory drugs, and aspirin in US women
Curhan, G. C., Bullock, A. J., Hankinson, S. E., Willett, W. C., Speizer, F. E., & Stampfer, M. J. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.732 · Cited by 54 · cited 1×
“In the Nurses’ Health Study (NHS) I survey (N1⁄4 86 985), 22% of US nurses aged 52 to 77 years reported use of APAP and 27% reported use of an NSAID at least once per week.(20) Among US nurses aged 33 to 51 years who participated in the NHS II survey (N 1⁄4 93 002), 25% reported using APAP and 42% reported using an NS…”
MethodDoes the varied use of NSAIDs explain the differences in the risk of myocardial infarction?
van Staa, T. P., Rietbrock, S., Setakis, E., & Leufkens, H. G. M. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01991.x · Cited by 50 · cited 2×
“Linear trends for cumulative or daily dose revealed no statistical differences between ibuprofen, diclofenac, and ibuprofen.(31) A nested case–control study from the Netherlands examined the risk of first hospitalization for MI or other CV events (unstable angina, cerebrovascular accident, transient ischemic attack [T…”
BackgroundMethodCryer, B., Berlin, R. G., Cooper, S. A., Hsu, C., & Wason, S. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.01.011 · Cited by 41
COX-2 selective inhibitors: analysis of the renal effects
Perazella, M. A. (2002) · Expert Opinion on Drug Safety · doi:10.1517/14740338.1.1.53 · Cited by 41
Nonprescription Ibuprofen: Side Effect Profile
Furey, S. A., Waksman, J. A., & Dash, B. H. (1992) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1992.tb04479.x · Cited by 41
Non-selective non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk.
Fanelli, A., Romualdi, P., Vigano', R., Aprile, P. L., Gensini, G., & Fanelli, G. C. (2013) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · Cited by 30
Furey, S. A., Vargas, R., & McMahon, F. G. (1993) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1993.tb02699.x · Cited by 22
Cited by
Urban, P., Mehran, R., Colleran, R., Angiolillo, D. J., Byrne, R. A., Capodanno, D., Cuisset, T., Cutlip, D., Eerdmans, P., Eikelboom, J., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.040167 · Cited by 823
Self-citationUrban, P., Mehran, R., Colleran, R., Angiolillo, D. J., Byrne, R. A., Capodanno, D., Cuisset, T., Cutlip, D., Eerdmans, P., Eikelboom, J., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz372 · Cited by 621
“NSAIDs represent the most widely used class of medications worldwide.(124,125) Both oral NSAIDs and steroids are associated with increased gastrointestinal bleeding risk, which is dose-dependent and increases with long-term use.”
BackgroundSelf-citationMallet, C., Desmeules, J., Pegahi, R., & Eschalier, A. (2023) · Journal of Pain Research · doi:10.2147/jpr.s393809 · Cited by 83
Alchin, J., Dhar, A., Siddiqui, K., & Christo, P. J. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2049551 · Cited by 65
Accelerated Atherosclerosis in Rheumatoid Arthritis: Mechanisms and Treatment
Reiss, A. B., Silverman, A., Khalfan, M., Vernice, N. A., Kasselman, L. J., Carsons, S. E., & Leon, J. D. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190430113212 · Cited by 42
Metadata
- Authors
- White, W. B., Kloner, R. A., Angiolillo, D. J., & Davidson, M. H.
- Affiliations
- University of Connecticut (US)
- University of Southern California (US)
- University of Florida (US)
- University of Chicago (US)
- Corresponding author
- White, William B.
- Venue
- Journal of Cardiovascular Pharmacology and Therapeutics
- Publisher
- SAGE Publications
- Published
- 2018-02-08
- Volume
- 23
- Issue
- 2
- Pages
- 103-118
- ISSN
- 1074-2484 (ISSN-L)
- 1940-4034
- PMC
- PMC5808827
- OpenAlex
- W2794398597
- Cited by
- 31
- References
- 55
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 3 · 2022: 4 · 2020: 12 · 2019: 6 · 2018: 1
- FWCI
- 0.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Cardiovascular Pharmacology and Therapeutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- over-the-counter analgesics, nonsteroidal anti-inflammatory drugs, ibuprofen, naproxen, paracetamol, cardiovascular risk, PRECISION trial, celecoxib, drug safety labeling, acute pain relief
- MeSH terms
- Acetaminophen, Analgesics, Drug Labeling, Nonprescription Drugs, Heart Diseases, Humans, Ibuprofen, Kidney Diseases, Naproxen, Risk Factors, Risk Assessment, Patient Safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.